Literature DB >> 28367056

Association study of MIF promoter polymorphisms with suicide completers in the Japanese population.

Naofumi Shimmyo1, Akitoyo Hishimoto1, Ikuo Otsuka1, Satoshi Okazaki1, Shuken Boku1, Kentaro Mouri1, Tadasu Horai1, Motonori Takahashi2, Yasuhiro Ueno2, Osamu Shirakawa3, Ichiro Sora1.   

Abstract

BACKGROUND: Numerous studies suggest that inflammation plays a key role in suicidal behavior. Macrophage migration inhibitory factor (MIF), a proinflammatory cytokine, has received increasing attention in depression research. However, no study has investigated whether MIF has genetic involvement in completed suicide. In this study, we sought to explore the relationship between two functional polymorphisms on the MIF gene promoter (MIF-794CATT5-8 microsatellite and MIF-173G/C single-nucleotide polymorphism [SNP]) and completed suicide by using one of the largest samples of suicide completers ever reported.
METHODS: The subjects comprised 602 suicide completers and 728 healthy controls. We genotyped MIF-794CATT5-8 microsatellite by polymerase chain reaction-based size discrimination assay and MIF-173G/C SNP by TaqMan® SNP genotyping assay. The allele-, genotype-, or haplotype-based association analyses between the suicide completers and the controls were carried out with the χ2 test, the Cochran-Armitage trend test, or Fisher's exact test.
RESULTS: Analyses of allele or genotype frequency distributions of the polymorphisms studied here did not reveal any significant differences between the suicide completers and the controls. Haplotype analysis also revealed no association with completed suicide.
CONCLUSION: To our knowledge, this is the first study that has examined the genetic association between MIF and completed suicide. Our results suggest that the effects of MIF-794CATT5-8 microsatellite and MIF-173G/C SNP on the MIF gene promoter might not contribute to the genetic risk of completed suicide in the Japanese population.

Entities:  

Keywords:  MIF; SNP; haplotype; microsatellite; promoter region; suicide

Year:  2017        PMID: 28367056      PMCID: PMC5370383          DOI: 10.2147/NDT.S130855

Source DB:  PubMed          Journal:  Neuropsychiatr Dis Treat        ISSN: 1176-6328            Impact factor:   2.570


Introduction

Suicide is a significant public health problem worldwide, with ~1 million suicides each year. A review of the literature showed that >2% of the current traffic accidents were suicide attempts, and this phenomenon may be underreported.1 The involvement of genetic factors in suicidal behavior is supported by family studies, twin and adoption studies, candidate gene analyses, and genome-wide association studies. Various studies have shown that numerous genes (eg, serotonin receptors and transporters, brain-derived neurotrophic factors [BDNF], or catechol-O-methyltransferase [COMT]) are linked to suicidal behavior, although conflicting reports exist.2,3 In addition, recent studies reported aberrant cytokine levels in blood, cerebrospinal fluid, and postmortem brain samples from suicidal completers.4 For instance, increased blood levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) are associated with suicidal ideation and attempt.5,6 Alternatively, mRNA and protein levels of IL-1β, IL-6, and TNF-α were increased postmortem in the prefrontal cortexes of teenaged suicide completers.7 Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine involved in the regulation of innate and adaptive immunity.8 MIF was originally identified as a product of T-lymphocytes on the basis of its ability to prevent random migration of macrophages.9,10 MIF is secreted in response to inflammatory stimuli, including microbial products and glucocorticoids.11,12 Upon release, MIF acts in an autocrine and paracrine manner to promote proinflammatory cytokine production, eg, IL-1β, IL-6, and TNF-α.13,14 MIF has also been shown to facilitate DNA damage response and cell cycle regulation.15 In addition, MIF production has been discovered in many other nonimmune cells ubiquitously, being highly expressed in the liver, kidneys, anterior pituitary, and brain.8,16 It is reported that MIF expression in the brain was seen in neurons of the cortex, hypothalamus, hippocampus, cerebellum, and pons,17 and in astrocytes and the subgranular zone of the hippocampus.18 Increasing evidence suggests a role for MIF in depression.19 Deletion of MIF resulted in increased depressive behaviors in rodent models.18 In addition, several studies have explored MIF as a biomarker in major depressive disorder (MDD) and other mood disorders. Some studies have identified increased serum MIF both in patients with MDD and in healthy subjects with depressive symptoms.20–22 Exhaustive serum proteomic profiling of MDD has identified MIF as one of the robust changed analytes in patients compared with controls.23,24 Furthermore, it has been established that MIF has an intricate relationship with the hypothalamic–pituitary–adrenal axis. For instance, Edwards et al25 found that elevated serum MIF was associated with depressive symptoms, reduced cortisol response to acute stress, and lower morning cortisol values. Alternatively, MIF was shown to specifically counteract the glucocorticoid-induced suppression of inflammatory cytokine secretion in activated macrophages (IL-1β, IL-6, and TNF-α).12 The hypothalamic–pituitary–adrenal axis has also gained interest as a neurobiological factor related to suicide, on the basis of the findings of studies investigating dexamethasone suppression test (DST) response, since nearly a 10-fold higher risk of completed suicide was found in DST nonsuppressors than in DST suppressors in a depressed cohort.2,26 From these findings, we hypothesized that MIF is involved in the genetic pathophysiology of suicide. The MIF gene promoter contains two functional variations: MIF-794CATT5–8 repeat (rs5844572) and MIF-173G/C single-nucleotide polymorphism (SNP) (rs755622), which have been well documented to affect the gene expression and protein levels of MIF.27,28 Indeed, many studies have examined the association between these two polymorphisms and various physical diseases.29–34 However, no previous study has investigated the role of both these polymorphisms in suicidal behavior. Hence, we investigated the association of the two functional polymorphisms on the MIF promoter in suicide using the large sample size of 602 suicide completers and 728 controls.

Materials and methods

Subjects

This study was approved by the Ethical Committee for Genetic Studies of Kobe University Graduate School of Medicine. The study population consisted of 602 suicide completers (408 males: mean age ± standard deviation (SD), 51.0±17.4 years; 194 females: 50.7±18.8 years) and 728 unrelated healthy volunteers (340 males: mean age ± SD, 53.3±18.8 years; 388 females: 54.5±18.3 years). All subjects were ethnically Japanese. Autopsies on suicide victims were conducted at the Department of Legal Medicine, Kobe University Graduate School of Medicine. The definition of suicide was based on the results of medicolegal examination and the police investigation as required by Japanese law. The methods of suicide were neck hanging (399), jumping from heights (100), gas suffocation (29), drowning (16), jumping in front of a vehicle (9), drug overdose (8), self-inflicted penetrating wounds (8), self-burning (3), taking poison (2), other methods (10), and unknown (18). We subdivided suicide completers into violent suicide (neck hanging, jumping from heights, gas suffocation, drowning, jumping in front of a vehicle, self-inflicted penetrating wounds, and self-burning) and nonviolent suicide (taking poison and drug overdose), according to Dumais et al.35 The healthy controls were recruited with consent after the purpose and procedures of the study were explained. The psychiatric assessment of each healthy participant was conducted as previously described.36,37 Briefly, none of them manifested psychiatric problems in unstructured interviews using unnamed symptom checklists based on the Diagnostic and Statistical Manual of Mental Disorders 4th edition criteria by two psychiatrists. Demographics of suicide completers and healthy controls are shown in Table 1. Informed consent was obtained from all of the participants and from the families of the subjects used for postmortem blood experiments.
Table 1

Demographics of suicide completers and healthy controls

SubjectsSuicide(n=602)Control(n=728)
Mean age ± SD50.9±17.954.0±18.5
n (male:female)408:194340:388
Suicide methods
 Neck hanging399
 Jumping from heights100
 Gas suffocation29
 Drowning16
 Jumping in front of vehicles9
 Drug overdosing8
 Self-inflicted penetrating wounds8
 Self-burning3
 Taking poison2
 Other10
 Unknown18

Abbreviation: SD, standard deviation.

Blood and DNA sampling

Peripheral blood was obtained from all suicide completers and controls. Blood samples were stored at −80°C before use. DNA was extracted using the QIAamp DNA Blood Midi Kit (Qiagen Inc., Valencia, CA, USA). Each DNA sample was quantified and qualified using a NanoDrop spectrophotometer (Thermo Scientific, Wilmington, DE, USA).

Genotyping for the MIF-794CATT5–8 repeat polymorphism (rs5844572)

Genomic DNA (100 ng) was subjected to polymerase chain reaction (PCR) for one cycle at 95°C for 10 minutes, followed by 40 cycles at 95°C for 30 seconds, 55°C for 30 seconds, 72°C for 30 seconds and final extension at 72°C for 7 minutes. The forward primer was 5′-TTG-CAC-CTA-TCA-GAG-ACC-3′ labeled with a carboxyfluorescein fluorescent dye, and the reverse primer was 5′-TCC-ACT-AAT-GGT-AAA-CTC-G-3′. The 25 μL PCR reaction volume contained 100 ng of genomic DNA, 12.5 μL of AmpliTaq Gold 360 Master Mix (Thermo Fisher Scientific, Waltham, MA, USA) and 1.0 μL of forward and reverse primer. The amplification included an initial holding at 95°C for 10 minutes, followed by a three-step PCR program: 95°C for 30 seconds, 55°C for 30 seconds, and 40 cycles at 72°C for 30 seconds, and finally, 72°C for 7 minutes. The PCR product was appropriately diluted and supplemented with GeneScan 600 size standard (Applied Biosystems, Foster City, CA, USA). The mixture was then separated on a 50-cm polyacrylamide gel at 15,000 V for 45 minutes on an ABI 3130 capillary sequencer and analyzed with GeneMapper® 4.0 software (Applied Biosystems). The PCR product sizes were 207 bp, 211 bp, and 215 bp in length, and these corresponded to 5-, 6-, and 7-CATT repeats, respectively. 8-CATT repeats were not observed in this study.

Genotyping for the MIF-173G/C SNP (rs755622)

We selected the predesigned TaqMan SNP genotyping assays from the Applied Biosystems database (http://www.appliedbiosystems.com) for the MIF-173G/C SNP (rs755622). Genotyping was performed with a 7500 Real-Time PCR System (Applied Biosystems) according to the manufacturer’s protocol.

Statistics

We used the Haploview version 4.2 software program (http://www.broad.mit.edu/mpg/haploview) to determine the Hardy–Weinberg equilibrium and allelic or haplotype frequencies for each of the MIF promoter polymorphisms.38 The allele-, genotype-, or haplotype-based association analyses between the suicide and control groups were carried out with the χ2 test, Cochran–Armitage trend test, or Fisher’s exact test, as appropriate, using Haploview software, R version 3.1.0 (The R Foundation for Statistical Computing, 2014, Vienna, Austria) and Excel 2010 (Microsoft, Redmond, WA, USA) with the Statcel3 add-on (OMS, Saitama, Japan). The power analysis was performed with the PS v2.1.3.1 program.39 Statistical significance for the two MIF polymorphisms study was defined as two-tailed P<0.05/2=0.025.

Results

MIF-794CATT5–8 repeat and MIF-173G/C SNP analyses

No deviation from Hardy–Weinberg equilibrium was seen in suicide completers and healthy controls for both polymorphisms. The MIF-794CATT5–8 repeat genotype and allele frequencies are shown in Table 2. Neither the genotype distribution nor the allelic frequency of the polymorphism was significantly associated with completed suicide. The MIF-173G/C SNP genotype and allele frequencies in suicide completers and healthy controls are shown in Table 3. Neither the genotype distribution nor the allelic frequency of the SNP was significantly associated with completed suicide. Subgroup analyses based on sex difference or methods of suicide (violent or nonviolent) also yielded no significant findings (Tables S1–S5).
Table 2

Association of MIF-794CATT5–8 repeat with suicide completers and controls

PolymorphismSuicide(n=602)
Control(n=728)
P-valueaGlobal P-valuebOR (95% CI)Power
NFrequencyNFrequency
MIF-794CATT5–8
Genotype
 55860.1431050.1450.9430.4090.99 (0.73–1.35)0.050
 562310.3842510.3450.1411.18 (0.95–1.48)0.313
 57770.128950.1300.8890.98 (0.71–1.35)0.051
 661110.1841580.2170.1400.82 (0.62–1.07)0.319
 67830.138930.1280.5871.09 (0.79–1.50)0.084
 77140.023260.0360.1850.64 (0.33–1.24)0.277
Allele
 CATT54800.3995560.3820.3760.6451.07 (0.92–1.25)0.146
 CATT65360.4456600.4530.6750.97 (0.83–1.13)0.070
 CATT71880.1562400.1650.5440.94 (0.76–1.15)0.096

Notes:

Genotypic P-values and allelic P-values were tested with the χ2 test.

Global P-values were calculated by Fisher’s exact test.

Abbreviations: MIF, macrophage migration inhibitory factor; OR, odds ratio; CI, confidence interval.

Table 3

Association of MIF-173 SNP with suicide completers and controls

PolymorphismSuicide(n=602)
Control(n= 728)
P-valueaGlobal P-valuebOR (95% CI)Power
NFrequencyNFrequency
MIF-173G/C
Genotype
 GG3730.6204510.6190.9970.7141.00 (0.83–1.21)0.050
 GC2030.3372370.3260.6531.05 (0.84–1.33)0.071
 CC260.043400.0550.3260.78 (0.47–1.29)0.168
Allele
 G9490.7881,1390.7820.7110.97 (0.80–1.16)0.066
 C2550.2123170.218

Notes:

Genotypic P-values and allelic P-values were tested with the χ2 test.

Global P-value was tested with the Cochran–Armitage test for trend.

Abbreviations: MIF, macrophage migration inhibitory factor; OR, odds ratio; CI, confidence interval.

MIF promoter haplotype analyses

Linkage disequilibrium between each CATT repeat and the −173C was measured as follows: CATT5 and −173C: D’ =0.495, r2=0.043; CATT6 and −173C: D’ =0.871, r2=0.170; CATT7 and −173C: D’ =0.984, r2=0.678. The CATT7 and −173C polymorphisms were observed in strong linkage disequilibrium in our samples. We then examined whether the different haplotypes of the MIF-794CATT5–8 repeat and the MIF-173G/C SNP would show different distribution patterns in suicide completers compared with controls. The reconstructed frequencies of each possible haplotype based on the observed genotype data are shown in Table 4. There were six haplotypes in this study, none of which showed different distributions between suicide completers and controls. Subgroup analyses based on sex difference or methods of suicide (violent or nonviolent) also showed no significance (Tables S1–S5).
Table 4

Association of haplotypes of MIF promoter polymorphisms with suicide completers and controls

HaplotypeSuicide(n=602)
Control(n=728)
P-valueaGlobal P-valuebOR (95% CI)Power
NFrequencyNFrequency
Haplotype
 MIFCATT5-173G4270.3554960.3410.4420.6311.06 (0.90–1.25)0.118
 MIFCATT6-173G5220.4336410.4400.7160.97 (0.83–1.13)0.065
 MIFCATT7-173G40.00310.0010.1294.14 (0.54–31.7)0.229
 MIFCATT5-173C530.044600.0410.7461.06 (0.73–1.55)0.068
 MIFCATT6-173C140.012190.0130.8020.92 (0.46–1.84)0.055
 MIFCATT7-173C1840.1532390.1640.4260.92 (0.75–1.13)0.096

Notes:

P-values were tested with the χ2 test.

Global P-value was calculated by Fisher’s exact test or Cochran–Armitage test for trend, as appropriate.

Abbreviations: MIF, macrophage migration inhibitory factor; OR, odds ratio; CI, confidence interval.

Discussion

To our knowledge, this is the first study to investigate the association between suicide and two functional polymorphisms in the MIF gene promoter, which are known to affect the gene expression and protein levels of MIF. We also conducted subgroup analysis to investigate sex differences because males tend toward a higher suicide rate than females do among all age groups worldwide.40 Furthermore, we determined differences between violent and nonviolent suicides in this study because lethality associated with violent methods is considerably higher than that associated with nonviolent methods.41 Moreover, some previous studies showed differences between subjects with violent vs nonviolent methods of suicide in other polymorphisms (for the COMT and BDNF genes) related to completed suicide.42,43 As a result, no significant differences were found in any of the analyses, which indicated that MIF-794CATT5–8 repeat microsatellite and MIF-173G/C SNP are not associated with an increased risk of suicide in the Japanese population. Recent meta-analyses with MDD cases also failed to show the genetic involvement of MIF.44,45 Therefore, MIF might not be primarily involved in genetic susceptibility to suicide (and depression). The limitations of the present study should be considered. First, the current sample provides low powers based on the observed frequencies of two polymorphisms. The number of subjects in the association study may not have been large enough to detect a significant difference, although our sample size of suicide completers was one of the largest ever reported. In fact, most previous candidate gene analyses and genome-wide association studies for completed suicide could not overcome the statistical limitation of small samples2,3,46 because it is extremely difficult to obtain tissue samples from suicide completers. Second, our study included only the Japanese population. The distribution of MIF polymorphisms determined by us was similar to that determined in the previous study for Japanese population by Llamas-Covarrubias et al,47 but not for Caucasian by Swanberg et al.48 Given that the MIF polymorphisms studied here differ among Caucasians, Africans, and Asians,49 our results might not be extrapolated to other populations. In addition, MIF protein levels in the brains of individuals displaying suicidal behavior should be further investigated to clarify the associations between MIF and suicide other than genetic susceptibility.

Conclusion

In conclusion, our results suggest that MIF-794CATT5–8 microsatellite and MIF-173G/C SNP microsatellite might not contribute to the genetic risk of completed suicide in the Japanese population. Association of MIF promoter polymorphisms with suicide completers and controls for males Notes: P-values were tested with the χ2 test. Global P-value was calculated by Fisher’s exact test or Cochran–Armitage test for trend, as appropriate. Abbreviations: MIF, macrophage migration inhibitory factor; OR, odds ratio; CI, confidence interval. Association of MIF promoter polymorphisms with suicide completers and controls for females Notes: P-values were tested with the χ2 test. Global P-value was calculated by Fisher’s exact test or Cochran–Armitage test for trend, as appropriate. Abbreviations: MIF, macrophage migration inhibitory factor; OR, odds ratio; CI, confidence interval. Association of MIF promoter polymorphisms with violent suicide completers and controls Notes: P-values were tested with the χ2 test. Global P-value was calculated by Fisher’s exact test or Cochran–Armitage test for trend, as appropriate. Abbreviations: MIF, macrophage migration inhibitory factor; OR, odds ratio; CI, confidence interval. Association of MIF promoter polymorphisms with nonviolent suicide completers and controls Notes: P-values were tested with the χ2 test. Global P-value was calculated by Fisher’s exact test or Cochran–Armitage test for trend, as appropriate. Abbreviations: MIF, macrophage migration inhibitory factor; OR, odds ratio; CI, confidence interval. Association of MIF promoter polymorphisms with violent and nonviolent suicide completers Notes: P-values were tested with the χ2 test. Global P-value was calculated by Fisher’s exact test or Cochran–Armitage test for trend, as appropriate. Abbreviations: MIF, macrophage migration inhibitory factor; OR, odds ratio; CI, confidence interval.
Table S1

Association of MIF promoter polymorphisms with suicide completers and controls for males

PolymorphismMale suicide(n=408)
Male control(n=340)
P-valueaGlobal P-valuebOR (95% CI)Power
NFrequencyNFrequency
MIF-794CATT5–8
Genotype
 55560.137490.1440.7880.5840.945 (0.625–1.429)0.059
 561590.3901190.3500.2631.186 (0.880–1.599)0.193
 57530.130440.1290.9841.004 (0.654–1.542)0.050
 66770.189770.2260.2040.795 (0.557–1.133)0.256
 67530.130380.1120.4501.187 (0.761–1.850)0.108
 77100.025130.0380.2790.632 (0.274–1.460)0.194
Allele
 CATT53240.3972610.3840.6010.8751.057 (0.858–1.303)0.080
 CATT63660.4493110.4570.7330.965 (0.787–1.184)0.061
 CATT71260.1541080.1590.8150.967 (0.731–1.280)0.058
MIF-173G/C
Genotype
 GG2520.6182180.6410.5070.7530.904 (0.671–1.218)0.100
 GC1360.3331020.3000.3301.167 (0.856–1.591)0.154
 CC200.049200.0590.5530.825 (0.436–1.560)0.097
Allele
 G6400.7845380.7910.7470.960 (0.748–1.231)0.062
 C1760.2161420.209
Haplotype
 MIFCATT5-173G2830.347234.10.3440.9200.7691.011 (0.816–1.253)0.052
 MIFCATT6-173G357.40.438300.60.4420.8750.984 (0.801–1.207)0.053
 MIFCATT7-173G2.10.0030.10.0000.20817.54 (0.031–9.989)0.000
 MIFCATT5-173C410.05026.90.0400.3201.284 (0.781–2.112)0.132
 MIFCATT6-173C8.60.01110.40.0150.4130.686 (0.276–1.702)0.111
 MIFCATT7-173C123.90.152107.90.1590.7150.949 (0.717–1.257)0.067

Notes:

P-values were tested with the χ2 test.

Global P-value was calculated by Fisher’s exact test or Cochran–Armitage test for trend, as appropriate.

Abbreviations: MIF, macrophage migration inhibitory factor; OR, odds ratio; CI, confidence interval.

Table S2

Association of MIF promoter polymorphisms with suicide completers and controls for females

PolymorphismFemale suicide(n=194)
Female control(n=388)
P-valueaGlobal P-valuebOR (95% CI)Power
NFrequencyNFrequency
MIF-794CATT5–8
Genotype
 55300.155560.1440.7410.8501.084 (0.670–1.755)0.066
 56720.3711320.3400.4611.145 (0.799–1.639)0.114
 57240.124510.1310.7930.933 (0.555–1.568)0.055
 66340.175810.2090.3390.805 (0.517–1.255)0.162
 67300.155550.1420.6781.108 (0.684–1.794)0.072
 7740.021130.0340.3840.607 (0.195–1.888)0.119
Allele
 CATT51560.4022950.3800.4700.7621.096 (0.854–1.407)0.112
 CATT61700.4383490.4500.7080.954 (0.746–1.219)0.067
 CATT7620.1601320.1700.6560.928 (0.667–1.290)0.070
MIF-173G/C
Genotype
 GG1210.6242330.6010.5890.3901.103 (0.774–1.572)0.082
 GC670.3451350.3480.9510.989 (0.688–1.420)0.050
 CC60.031200.0520.2560.587 (0.232–1.487)0.196
Allele
 G3090.7966010.7740.3941.139 (0.845–1.536)0.089
 C790.2041750.226
Haplotype
 MIFCATT5-173G143.70.370262.60.3380.2800.5191.150 (0.892–1.483)0.187
 MIFCATT6-173G164.30.423340.60.4390.6150.939 (0.734–1.201)0.081
 MIFCATT7-173G2.10.0051.10.0010.2333.834 (0.380–38.62)0.071
 MIFCATT5-173C12.30.03232.40.0420.3980.751 (0.385–1.465)0.124
 MIFCATT6-173C5.70.0158.40.0110.5641.362 (0.467–3.975)0.092
 MIFCATT7-173C59.90.154130.90.1690.5380.900 (0.645–1.256)0.098

Notes:

P-values were tested with the χ2 test.

Global P-value was calculated by Fisher’s exact test or Cochran–Armitage test for trend, as appropriate.

Abbreviations: MIF, macrophage migration inhibitory factor; OR, odds ratio; CI, confidence interval.

Table S3

Association of MIF promoter polymorphisms with violent suicide completers and controls

PolymorphismViolent suicide(n=568)
Control(n=728)
P-valueaGlobal P-valuebOR (95% CI)Power
NFrequencyNFrequency
MIF-794CATT5–8
Genotype
 55820.1441050.1440.9950.3131.001 (0.733–1.368)0.050
 562200.3872510.3450.1141.201 (0.957–1.509)0.329
 57700.123950.1300.6970.937 (0.673–1.303)0.066
 661050.1851580.2170.1530.818 (0.621–1.078)0.309
 67790.139930.1280.5511.103 (0.799–1.522)0.088
 77120.021260.0360.1220.583 (0.291–1.165)0.387
Allele
 CATT54540.4005560.3820.3570.5541.078 (0.919–1.263)0.152
 CATT65090.4486600.4530.7910.979 (0.838–1.144)0.057
 CATT71730.1522400.1650.3870.910 (0.736–1.126)0.148
MIF-173G/C
Genotype
 GG3550.6254510.6200.8400.5421.024 (0.816–1.284)0.054
 GC1900.3352370.3260.7341.041 (0.825–1.315)0.063
 CC230.040400.0550.2300.726 (0.429–1.227)0.250
Allele
 G9000.7921,1390.7820.5391.061 (0.878–1.283)0.094
 C2360.2083170.218
Haplotype
 MIFCATT5-173G406.80.358496.70.3410.3690.5471.077 (0.916–1.268)0.145
 MIFCATT6-173G494.80.436640.90.4400.8120.981 (0.839–1.148)0.055
 MIFCATT7-173G4.10.0041.20.0010.1134.391 (0.573–33.63)0.057
 MIFCATT5-173C47.20.04259.30.0410.9151.021 (0.691–1.509)0.052
 MIFCATT6-173C14.20.01319.10.0130.9000.952 (0.477–1.901)0.050
 MIFCATT7-173C168.90.149238.80.1640.2860.890 (0.718–1.103)0.184

Notes:

P-values were tested with the χ2 test.

Global P-value was calculated by Fisher’s exact test or Cochran–Armitage test for trend, as appropriate.

Abbreviations: MIF, macrophage migration inhibitory factor; OR, odds ratio; CI, confidence interval.

Table S4

Association of MIF promoter polymorphisms with nonviolent suicide completers and controls

PolymorphismNonviolent suicide(n=10)
Control(n=728)
P-valueaGlobal P-valuebOR (95% CI)Power
NFrequencyNFrequency
MIF-794CATT5–8
Genotype
 5510.1001050.1440.6920.8900.659 (0.083–5.258)0.037
 5650.5002510.3450.3061.900 (0.545–6.626)0.187
 5710.100950.1300.7760.740 (0.093–5.910)0.036
 6610.1001580.2170.3710.401 (0.050–3.188)0.073
 6720.200930.1280.4981.707 (0.357–8.161)0.152
 7700.000260.0360.543
Allele
 CATT580.4005560.3820.8681.0001.079 (0.438–2.656)0.055
 CATT690.4506600.4530.9770.987 (0.406–2.396)0.050
 CATT730.1502400.1650.8590.894 (0.260–3.075)0.045
MIF-173G/C
Genotype
 GG60.6004510.6200.8400.8520.921 (0.258–3.294)0.054
 GC40.4002370.3260.8741.381 (0.386–4.941)0.089
 CC00.000400.0550.953
Allele
 G160.8001,1390.7820.9351.113 (0.370–3.353)0.047
 C40.2003170.218
Haplotype
 MIFCATT5-173G6.80.340496.60.3410.9800.9710.995 (0.392–2.526)0.050
 MIFCATT6-173G8.90.445641.20.4400.9651.019 (0.419–2.476)0.050
 MIFCATT7-173G0.00.0001.00.0010.907
 MIFCATT5-173C1.20.06059.40.0410.6421.501 (0.233–9.675)0.120
 MIFCATT6-173C0.10.00518.80.0130.7440.384 (0.001–195.1)0.004
 MIFCATT7-173C3.00.150239.00.1640.8630.899 (0.261–3.090)0.045

Notes:

P-values were tested with the χ2 test.

Global P-value was calculated by Fisher’s exact test or Cochran–Armitage test for trend, as appropriate.

Abbreviations: MIF, macrophage migration inhibitory factor; OR, odds ratio; CI, confidence interval.

Table S5

Association of MIF promoter polymorphisms with violent and nonviolent suicide completers

PolymorphismViolent suicide(n=568)
Nonviolent suicide(n=10)
P-valueaGlobal P-valuebOR (95% CI)Power
NFrequencyNFrequency
MIF-794CATT5–8
Genotype
 55820.14410.1000.6920.9401.519 (0.190–12.15)0.032
 562200.38750.5000.4690.632 (0.181–2.209)0.134
 57700.12310.1000.8241.265 (0.158–10.13)0.036
 661050.18510.1000.4922.041 (0.256–16.29)0.031
 67790.13920.2000.5820.646 (0.135–3.099)0.139
 77120.02100.0000.642
Allele
 CATT54540.40080.4000.9981.0000.999 (0.405–2.462)0.050
 CATT65090.44890.4500.9860.992 (0.408–2.413)0.050
 CATT71730.15230.1500.9781.018 (0.295–3.511)0.049
MIF-173G/C
Genotype
 GG3550.62560.6000.8710.9321.111 (0.310–3.982)0.056
 GC1900.33540.4000.6640.754 (0.210–2.704)0.085
 CC230.04000.0000.516
Allele
 G9000.792160.8000.9330.953 (0.316–2.878)0.048
 C2360.20840.200
Haplotype
 MIFCATT5-173G406.00.3576.80.3400.8580.9731.080 (0.425–2.745)0.050
 MIFCATT6-173G494.60.4358.90.4450.9320.962 (0.395–2.341)0.051
 MIFCATT7-173G4.30.0040.00.0000.800
 MIFCATT5-173C48.00.0421.20.0600.6660.691 (0.107–4.475)0.121
 MIFCATT6-173C14.40.0130.10.0050.7602.555 (0.005–1.304)0.003
 MIFCATT7-173C168.70.1493.00.1500.9880.988 (0.287–3.409)0.051

Notes:

P-values were tested with the χ2 test.

Global P-value was calculated by Fisher’s exact test or Cochran–Armitage test for trend, as appropriate.

Abbreviations: MIF, macrophage migration inhibitory factor; OR, odds ratio; CI, confidence interval.

  49 in total

1.  The dexamethasone suppression test and suicide prediction.

Authors:  W Coryell; M Schlesser
Journal:  Am J Psychiatry       Date:  2001-05       Impact factor: 18.112

2.  MIF expression in the rat brain: implications for neuronal function.

Authors:  M Bacher; A Meinhardt; H Y Lan; F S Dhabhar; W Mu; C N Metz; J A Chesney; D Gemsa; T Donnelly; R C Atkins; R Bucala
Journal:  Mol Med       Date:  1998-04       Impact factor: 6.354

3.  The association between catechol-O-methyl-transferase Val108/158Met polymorphism and suicide.

Authors:  N Pivac; P Pregelj; M Nikolac; T Zupanc; G Nedic; D Muck Seler; A Videtic Paska
Journal:  Genes Brain Behav       Date:  2011-05-03       Impact factor: 3.449

4.  Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims.

Authors:  Ghanshyam N Pandey; Hooriyah S Rizavi; Xinguo Ren; Jawed Fareed; Debra A Hoppensteadt; Rosalinda C Roberts; Robert R Conley; Yogesh Dwivedi
Journal:  J Psychiatr Res       Date:  2011-09-08       Impact factor: 4.791

5.  Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1.

Authors:  R Kleemann; A Hausser; G Geiger; R Mischke; A Burger-Kentischer; O Flieger; F J Johannes; T Roger; T Calandra; A Kapurniotu; M Grell; D Finkelmeier; H Brunner; J Bernhagen
Journal:  Nature       Date:  2000-11-09       Impact factor: 49.962

6.  Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis.

Authors:  M A Llamas-Covarrubias; Y Valle; R Bucala; R E Navarro-Hernández; C A Palafox-Sánchez; J R Padilla-Gutiérrez; I Parra-Rojas; A G Bernard-Medina; Z Reyes-Castillo; J F Muñoz-Valle
Journal:  Cytokine       Date:  2013-02-09       Impact factor: 3.861

Review 7.  MIF: mood improving/inhibiting factor?

Authors:  Joshua Bloom; Yousef Al-Abed
Journal:  J Neuroinflammation       Date:  2014-01-21       Impact factor: 8.322

Review 8.  Genetic Association Studies of Suicidal Behavior: A Review of the Past 10 Years, Progress, Limitations, and Future Directions.

Authors:  Bojan Mirkovic; Claudine Laurent; Marc-Antoine Podlipski; Thierry Frebourg; David Cohen; Priscille Gerardin
Journal:  Front Psychiatry       Date:  2016-09-23       Impact factor: 4.157

9.  The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor.

Authors:  T Calandra; J Bernhagen; R A Mitchell; R Bucala
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

10.  A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still's disease.

Authors:  Fang-Fang Wang; Xin-Fang Huang; Nan Shen; Lin Leng; Richard Bucala; Shun-Le Chen; Liang-Jing Lu
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

View more
  1 in total

1.  Association of MIF gene polymorphisms with pemphigus vulgaris: a case-control study with comprehensive review of the literature.

Authors:  Parikshaa Gupta; Neha Joshi; Shradha Uprety; Sunil Dogra; Dipankar De; Sanjeev Handa; Ranjana Walker Minz; Sukhvinder Singh; Seema Chhabra
Journal:  Int J Clin Exp Pathol       Date:  2021-11-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.